La Jolla, California–(Newsfile Corp. – February 24, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp” or the “Company”) a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today the company has been invited to present at the Stifel GMP Healthcare Conference: Healthcare Psychedelics: Addressing the Global Mental…


Previous articleBeckley Psytech appoints ex-pharma CEO as Chief Operating Officer
Next articleEntheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences